Clinical Trial Update: Re-expression of ER in Triple Negative Breast Cancers [Phase 1, Phase 2]

View source ↗

Summary

This update reports results from a Phase 1/2 trial evaluating re-expression of the estrogen receptor in triple-negative breast cancer. The study was terminated …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Snippet

Sponsor: Emory University | Conditions: Breast Cancer, Breast Tumors | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2015-01-26